1-Shanju kumar SL ,sharma R. (2000) Purification and charicerization of intestinal adenosine deaminase from mice . Mol cell Biol. ; 204:127-34
2- Koizumi H. Tomizawa K. Tanaka H. Kumaki M. Ohkamana A. (1993): J. of dermatology 20(7) : 394-399
3-Sari RA. Taysi S. Yilmaz O. (2003( Correlation of serum levels of adenosen daminase activety and its isoenzymes with disease activity in rheumatoid arthritis .Clin Exp Rheumatol 21:87-90,
4- Rokayan SA. (2003)Serum adenosine deaminase activity and its isoenzyme in patients treated for tuberculosis. J cell physicians surgpak. 13;11-4,
5- Cristalli G. Costanzi S. Lambertucci C. Lupidi G.Vittori S. Volpini R. Camaioni E(2001): Adenosin daminase functional implications and different classes of inhibition . Med. Res. Rev.;21:105-28Medline
6-Rohani MY. Cheong YM. Mohdrani JM.(1995) Malaysia .J.Pathol. 17(2):67-71
7-المرعب ,صفاء رزوقی (1988):الکیمیاء التحلیلیة :مدخل إلى طرائق الفصل ,جامعة بغداد –کلیة التربیة
8- Baron EJ. And Finegdd S.M(1990). 8thed the C.V. mosby company Baltimor ,Philadelphia ,Torento
9- Bergmeyer H.U. Bergmeyer(1983) J.Garbl M.: Method of enzymatic analysis Vol. IV Enzymes 2ed Ferdol Ropublic of grermany ;verlag chemic GmbH. Weinheim ,30:8-23
10- Tibor A.,Aman E., wergifosse P.,Clocckert A., Imet J.N. and Letesson J. (1983): J. Infect. Immun. 64(1): 100-107 10-Stone T.W.:Purine receptor and their pharmacological roles: (1989) .Adv. Drug Res ;18:291-429
11- Stone T.W.(1989).purine receptors and their pharmacological roles .Adv Drug Res.18: 291-429
12-Lucantonioli , Matteoforanai ,Rocchina colucci ,Norcisa,Ghisu,Federico dasettimo ,Gionfranco ,Notale, Olgakastsin chenka, etal, (2007) Inhibition of adenosine daminase attenuates inflammation in experimental colitis : J. of pharmacological and experimental therapeutics:322;435-442
13- Kuno M., Seki nobuo , Tsujimoto S., Nakanishi ,Isao K.T.;Nakamara K.,Terasaka T.Nishio N.,SatoA. (2006), .Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938:European journal of pharmacology ,534(1); 241-249 .
)
